The evolution of renin-angiotensin blockade: Angiotensin-converting enzyme inhibitors as the starting point

Current Hypertension Reports

Volumn 12, Issue 2, 2010, Pages 67-73

  Sica, Domenic A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Angiotensin receptor blockers; End organ disease; Hypertension; Renin inhibitors; Renin angiotensin system

Indexed keywords

AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; CANDESARTAN HEXETIL; CAPTOPRIL; CAPTOPRIL PLUS HYDROCHLOROTHIAZIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENALAPRIL MALEATE; ENALAPRIL MALEATE PLUS FELODIPINE; ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; EPROSARTAN; FELODIPINE; FOSINOPRIL; FOSINOPRIL PLUS HYDROCHLOROTHIAZIDE; FOSINOPRILAT; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; HYDROCHLOROTHIAZIDE PLUS MOEXIPRIL; HYDROCHLOROTHIAZIDE PLUS QUINAPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN POTASSIUM; MOEXIPRIL; OLMESARTAN; PERINDOPRIL; QUINAPRIL; RAMIPRIL; RENIN INHIBITOR; TELMISARTAN; TRANDOLAPRIL; TRANDOLAPRIL PLUS VERAPAMIL; TRANDOLAPRILAT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN; ZESTERETIC;

BLOOD PRESSURE REGULATION; CARDIAC PATIENT; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MARKETING; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG TARGETING; DRUG TOLERABILITY; ERYTHROCYTOSIS; FEVER; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; KIDNEY CLEARANCE; LEUKOPENIA; LIPOPHILICITY; LOW DRUG DOSE; PRESCRIPTION; PROTEINURIA; RASH; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TASTE DISORDER; UNSPECIFIED SIDE EFFECT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DIURETICS; HISTORY, 20TH CENTURY; HUMANS; HYPERTENSION; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 77953537318     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-010-0091-9     Document Type: Review

References (49)

1. Sica D, Gehr TW: Angiotensin converting enzyme inhibitors. In Hypertension, A Companion to the Kidney, edn 2. Edited by Oparil S, Weber M. Philadelphia: WB Saunders; 2005:669-682.
2. Lant AF: Evolution of diuretics and ACE inhibitors, their renal and antihypertensive actions - parallels and contrasts. Br J Clin Pharmacol 1987, 23:27S-41S.
3. Sica DA: Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002, 62:443-462.
4. Hoyer J, Schulte KL, Lenz T: Clinical pharmacokinetics of angiotensin converting enzyme inhibitors in renal failure. Clin Pharmacokinet 1993, 24:230-254.
5. Dzau VJ, Bernstein K., Celermajer D., et al.: The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 2001, 88(Suppl 9):1L-20L.
6. Reid JL: Kinetics to dynamics: are there differences between ACE inhibitors? Eur Heart J 1997, 18(Suppl E):E14-E18.
7. White CM: Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors. Pharmacotherapy 1998, 18:588-599.
8. Dickstein K: Pharmacokinetics of enalapril in congestive heart failure. Drugs 1986, 32(Suppl 5):40-44.
9. Sica DA, Cutler RE, Parmer R.J., Ford NF: Comparison of the steadystate pharmacokinetics of fosinopril, lisinopril, and enalapril in patients with chronic renal insufficiency. Clin Pharmacokinet 1991, 20 420-427.
10. Schoolwerth A, Sica DA, Ballermann B.J., Wilcox CS: Renal considerations in angiotensin converting enzyme inhibitor therapy. A statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 2001, 104:1985-1991.
11. Brown NJ, Vaughn DE: Angiotensin-converting enzyme inhibitors. Circulation 1998, 97:1411-1420.
12. Fabris B, Yamada H., Cubela R., et al.: Characterization of cardiac angiotensin converting enzyme and in vivo inhibition following oral quinapril to rats. Br J Pharmacol 1990, 100:651-655.
13. Johnston CI, Fabris B., Yamada H., et al.: Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. J Hypertens 1989, 7(Suppl):S11-S16. (Pubitemid 19269331)
14. Kinoshita A, Urata H., Bumpus F.M., Husain A: Measurement of angiotensin I converting enzyme inhibition in the heart. Circ Res 1993, 73:51-60. (Pubitemid 23173055)
15. Yusuf S, Sleight P., Pogue J., et al.: Effects of an angiotensin- converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-153.
16. Leonetti G, Cuspidi C: Choosing the right ACE inhibitor. A guide to selection. Drugs 1995, 49:516-535.
17. Kesselheim AS, Misono AS, Lee J.L., et al.: Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 2008, 300:2514-2526.
18. Materson BJ, Reda DJ, Cushman W.C., et al.: Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med 1993, 328:914-921.
19. Bravo EL, Tarazi RC: Converting enzyme inhibition with an orally active compound in hypertensive man. Hypertension 1979, 1:39-46.
20. Textor SC, Gephardt GN, Bravo E.l., et al.: Membranous glomerulopathy associated with captopril therapy. Am J Med 1983, 74:705-712.
21. Stumpe KO, Koloch R., Overlack A: Captopril and enalapril: evaluation of therapeutic efficacy and safety. Therapie Woche 1984, 34:3290-3298. (Pubitemid 14104120)
22. Zannad F, Matzinger A., Larché J: Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists. Am J Hypertens 1996, 9:633-643.
23. Elliott WJ: Therapeutic trials comparing angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Curr Hypertens Rep 2000, 2:402-411.
24. Andersen K, Weinberger MH, Egan B., et al: Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 2008, 26:589-599.
25. Izzo JL, Sica DA: Antihypertensive drugs: pharmacologic principles and dosing effect. In Hypertension Primer, edn 4. Edited by Izzo JL, Sica DA, Black HR Baltimore: Lippincott, Williams & Wilkins; 2008:432-434.
26. Schiffrin EL: Effects of antihypertensive drugs on vascular remodeling: Do they predict outcome in response to antihypertensive therapy? Curr Opin Nephrol Hypertens 2001, 10:617-624.
27. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
28. Lewis EJ, Hunsicker LG, Clarke WR et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
29. Halkin A, Keren G: Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular disease. Am J Med 2002, 112:126-134.
30. Blood Pressure Lowering Treatment Trialists' Collaboration, Turnbull F, Neal B, et al.: Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007, 25:951-958.
31. Garg R, Yusuf S: Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995, 273:1450-1456.
32. ACE Inhibitor Myocardial Infarction Collaborative Group: Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic review of individual data from 100,000 patients in randomised trials. Circulation 1998, 97:2202-2212.
33. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002, 288:1981-1997.
34. Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003, 362:782-788.
35. Lopez-Sendon J., Swedberg K., McMurray J., et al.: Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J 2004, 25:1454-1470.
36. Wing LM, Reid CM, Ryan P., et al: A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2002, 348:583-592.
37. Shekelle PG, Rich MW, Morton S.C., et al.: Efficacy of ACE inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003, 41:1529-1538.
38. Ezekowitz J, McAlister FA, Humphries K.H., et al.: The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 2004, 44:1587-1592.
39. Chobanian AV, Bakris GL, Black H.R., et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
40. Lewis EJ, Hunsicker LG, Bain R.P., Rohde RD: The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329:1456-1462.
41. Ravid M, Lang R., Rachmani R., et al.: Long-term renoprotective effect of angiotensin converting enzyme inhibition in non-insulin dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 1996, 156:286-289.
42. Viberti G, Mogensen CE, Groop L.C., Pauls JF: Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 1994, 271:275-279.
43. Giatras I, Lau J., Levey AS: Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med 1997, 127:337-345.
44. Agodoa LY, Appel L., Bakris GL et al.: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001, 285:2719-2728.
45. Sica DA: Angiotensin-converting enzyme inhibitors side effects - physiologic and non-physiologic considerations. J Clin Hypertens (Greenwich) 2004, 6:410-416.
46. Granger CB, McMurray JJ, Yusuf S., et al: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003, 362:772-776. (Pubitemid 37093917)
47. Sica DA: The Heart Outcomes Prevention Evaluation study: angiotensin-converting enzyme inhibitors: Are their benefits a class effect or do individual agents differ? Curr Opin Nephrol Hypertens 2001, 10:597-601.
48. David D, Jallad N., Germino F.W., et al.: A comparison of the cough profile of fosinopril and enalapril in hypertensive patients with a history of ACE Inhibitor-associated cough. Am J Ther 1995, 2:806-813.
49. Sharif MN, Evans BL, Pylypchuk GB: Cough induced by quinapril with resolution after changing to fosinopril. Ann Pharmacother 1994, 28:720-722.